Horseshoe crab blood is key to making a Covid-19 vaccine – but the ecosystem may suffer

In 2016 a synthetic alternative (rFC) to horseshoe crab blood, used in bacterial infection detection for injectable procedures, was licensed. And yet horseshoe crabs are both threatened with extinction and in line for preservation due to Covid-19 and its...

Continue reading →

Competition lowers drug prices, FDA says

According to a report by the US Food and Drug Administration (FDA), increased generic drug entry will lead to price reductions in the market (see our table below) as well as huge savings opportunities for patients, or at least...

Continue reading →

Doctors may be missing illnesses because UK medical textbooks often focus on white people

Malone Mukwende, a medical student from St. George's, University of London noticed during his studies that there was a problem with Ethnic Dermatology. Mr Mukwende's observation leads us to wider questions over healthcare investment opportunities, telemedicine, remote patient monitoring,...

Continue reading →

Will government contracts to produce PPE promote UK small-cap businesses globally?

● The UK government's PPE contracts surged, as of the beginning of July, and were, at least in part, awarded to smaller companies (see exhibit below). It is about more than just the cash, however welcome that it...

Continue reading →

Breakthrough studies on monoclonal antibodies

Researchers at Vanderbilt University Medical Centre (VUMC), based in Amsterdam, have recently published optimistic results from monoclonal antibody preclinical trials in Nature Medicine that could potentially be a breakthrough in the search for both a curative for the Covid-19...

Continue reading →

Hospital margins are down – is selling your health data a solution

A framework allowing a more sensible approach to health data collection In our previous blog we outlined the pressure on hospital margins and the entire hospital business model as a direct result of Covid-19. One solution is the sale by...

Continue reading →

Is producing a non-profit Covid-19 vaccine a smart decision for AstraZeneca and the industry

AZN's market-cap breached the £100bn break-out line thanks to the Covid-crisis, the British pharma giant promised that during the pandemic it won’t make profit on the vaccine, but maybe it should.         AZN.L relative 12m share price performance (lighter line) vs....

Continue reading →

Will virtual trial models provide the Covid-19 vaccine faster?

Covid-19 has given us a glimpse into the long and costly process of drug development. While health experts are speculating on a covid-19 vaccine by 2021, the reality is that the drug development process can take about 10-15 years...

Continue reading →

Could your facemask kill Coronavirus with electricity?

At the moment there isn't any underlying evidence as to whether or not a face mask could kill the Covid-19 virus using electricity as indicated in the story on 5th June 2020 in Popular Mechanics (which we summarise below),...

Continue reading →

Will the FDA speed up the approval of new drugs?

The Food and Drug Administration (FDA - US healthcare regulator) will endeavour to review many drugs applications in the next year in relation to coronavirus, but concerns are emerging that if the FDA follows its old ways it will...

Continue reading →